New blood thinner trial aims to prevent rebleeding in liver patients

NCT ID NCT07602062

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the blood thinner rivaroxaban can safely improve outcomes in people with liver cirrhosis who have both a blood clot in the portal vein and a high risk of variceal bleeding. About 175 participants will receive rivaroxaban or standard care starting 48 hours after endoscopic treatment. The goal is to see if it reduces rebleeding, clot worsening, and other serious complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rivaroxaban (a blood thinner)
What this could lead to: If it works, this could offer a safer way to manage blood clots in cirrhosis patients and reduce the risk of rebleeding and other complications.
What could go wrong: This is an early-stage trial with only 175 participants, so results may not apply to everyone. The main risk is bleeding, which could be serious in these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTICOAGULANT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices with bleeding portal vein thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTICOAGULANT THERAPY PORTAL VEIN THROMBOSIS VARICEAL BLEEDING

Contacts and locations

Locations

Dr. Huang xiaoquan

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.